Gamida Cell to Present NAM-Enabled, Genetically Modified NK

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day




●

... | October 26, 2021

Related Keywords

Dana Farber Cancer Institute , Massachusetts , United States , Boston , American , Courtney Turiano , Rhiannon Jeselonis , Julian Adams , Ronit Simantov , Stern Investor Relations Inc , Twitter , Drug Administration , Nasdaq , Exchange Commission , American Society Of Hematology , Gamida Cell Ltd , Gamida Cell , Genetically Modified , Therapy Pipeline , Clinical Hold , New Drug , Chief Executive Officer , Therapy Programs , Chief Medical Officer , Annual Meeting , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Investor Relations , Gamida Cell Ltd Stock Exchange , News , Information , Press Release , Shamida , Fell , O , Present , Genetically , Odified , Uk , Therapy , Pipeline , End , Update , N , It , Irtual Gmda Il0011552663 ,